Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02876510 | ACTolog in Patients With Solid Cancers | PHASE1 | COMPLETED | 38 | — | — | Jun 30, 2017 | Sep 22, 2021 | Feb 4, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| IMA101 product only (Cohort 1) | EXPERIMENTAL | * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * Infusion of the IMA101 T-cell product(s) * Post-infusion administration of low-dose recombinant human interleukin-2 |
| IMA101 product + atezolizumab (Cohort 2) | EXPERIMENTAL | * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * Infusion of the IMA101 T-cell product(s) * Post-infusion administration of low-dose recombinant human interleukin-2 * Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year |
| Name | Type | Description |
|---|---|---|
| Fludarabine | DRUG | Fludarabine infusion |
| Cyclophosphamide | DRUG | Cyclophosphamide infusion |
| IMA101 product | BIOLOGICAL | i.v. infusion of IMA101 product(s). |
| Recombinant human interleukin-2 | BIOLOGICAL | Low dose IL-2 Infusion for two weeks |
| IMADetect | DIAGNOSTIC_TEST | IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only. |
| Atezolizumab | DRUG | Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion. |
Inclusion Criteria: 1. Patients must have pathologically confirmed advanced/metastatic cancer prior to enrollment. 2. HLA phenotype positive. 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 4. Life expectancy \> 6 months prior to enrollment. 5. Patient is a candidate for a maxi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |